• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Social Capital Suvretta Holdings Corp. I filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    12/23/22 4:12:04 PM ET
    $DNAA
    Get the next $DNAA alert in real time by email
    8-K
    NASDAQ false 0001850266 0001850266 2022-12-22 2022-12-22

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of Earliest Event Reported):

    December 23, 2022 (December 22, 2022)

     

     

    Akili, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-40558   98-1586159

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    125 Broad Street, Fifth Floor,
     
    Boston MA   02110
    (Address of Principal Executive Offices)   (Zip Code)

    (617) 456-0597

    (Registrant’s telephone number, including area code)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange

    on which registered

    Common stock, par value $0.0001 per share   AKLI   Nasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 1.01

    Entry into a Material Definitive Agreement.

    On December 22, 2022, Akili, Inc., a Delaware corporation (the “Company”), and its wholly-owned subsidiary, Akili Interactive Labs, Inc., a Delaware corporation (the “Existing Borrower”) (the Company and the Existing Borrower collectively, the “Borrower”), entered into a Joinder and First Loan Modification Agreement (the “Loan Modification Agreement”) between the Borrower and Silicon Valley Bank, in its capacity as administrative agent and collateral agent (the “Agent”), and Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P., as lenders (the “Lenders”). The Loan Modification Agreement modifies certain sections of the Amended and Restated Loan and Security Agreement dated as of May 25, 2021, among the Borrower, the Lenders and the Agent (the “Original Loan Agreement”).

    The Loan Modification Agreement joins the Company to the Original Loan Agreement as a borrower. The Loan Modification Agreement also amends the Original Loan Agreement to decrease the Lenders’ Term A Loan Advance (as defined in the Original Loan Agreement) commitment from an original principal amount of up to $35,000,000 to an original principal amount of up to $25,000,000 while extending the expiration of the Term A Loan Draw Period (as defined in the Original Loan Agreement) to March 31, 2023, and to increase the Lenders’ Term C Loan Advance (as defined in the Original Loan Agreement) commitment from an original principal amount of up to $10,000,000 to an original principal amount of up to $20,000,000. As of September 30, 2022, there was $15.0 million outstanding pursuant to the terms of the Original Loan Agreement.

    The foregoing description of the Loan Modification Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Loan Modification Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    Item 2.03

    Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

    The information set forth in response to Item 1.01 of this Current Report on Form 8-K above regarding the Loan Modification Agreement is incorporated by reference in response to this Item 2.03 of this Current Report on Form 8-K.

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits.

     

    No.

       Description of Exhibit
    10.1    Joinder and First Loan Modification Agreement, dated December 22, 2022, by and among Silicon Valley Bank, in its capacity as administrative agent and collateral agent, Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P., as lenders, and Akili, Inc. and Akili Interactive Labs, Inc., as borrowers.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Akili, Inc.
    By:  

    /s/ Santosh Shanbhag

    Name:   Santosh Shanbhag
    Title:   Chief Financial Officer

    Date: December 23, 2022

    Get the next $DNAA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DNAA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DNAA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PureTech Health plc – Half-Year Report

      Strong capital base with PureTech Level Cash and Cash Equivalents of $341.4 million1 and Consolidated Cash and Cash Equivalents of $365.9 million2 as of June 30, 2022, excluding up to $115.4 million added post-period3; Operational runway extended into Q1 2026 Significant advancement of PureTech's Wholly Owned Programs, with three clinical trials underway, four completed, and human proof-of-principle achieved for a key PureTech platform Excellent progress across the Founded Entities, including Karuna's positive topline Phase 3 results for KarXT in schizophrenia, Akili's Nasdaq listing and Gelesis' commercial progress with Plenity®4 in the post-period, and four clinical data publications ac

      8/25/22 2:07:00 AM ET
      $CPSR
      $DNAA
      $GLS
      $KRTX
      Business Services
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Digital Medicine Leader Akili to List on Nasdaq Following Successful Business Combination with Social Capital Suvretta Holdings Corp. I

      Akili, Inc. common stock to begin trading on Nasdaq under the ticker symbol "AKLI" on August 22, 2022 Total gross proceeds of more than $163 million will support launch of first FDA-cleared video game treatment and advancement of late-stage pipeline Akili, a leading digital medicine company, today completed its previously announced business combination with Social Capital Suvretta Holdings Corp. I ("SCS") (NASDAQ:DNAA), a publicly traded special purpose acquisition company. The newly formed company, Akili, Inc. ("Akili"), is expected to start trading on The Nasdaq Capital Market ("Nasdaq") under the new ticker symbol "AKLI" on August 22, 2022. Akili raised more than $163 million from the

      8/19/22 5:25:00 PM ET
      $DNAA
    • PureTech Founded Entity Akili Announces Public Company Board of Director Nominees

      New and recent director nominees include industry trailblazers BJ Jones of Biohaven Pharmaceuticals; Christine Lemke of Evidation Health; Ken Ehlert, formerly of UnitedHealth Group; and Chamath Palihapitiya of Social Capital and SCS PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company noted that its Founded Entity, Akili Interactive Labs, Inc. ("Akili"), a leading digital medicine company pioneering the development of cognitive treatments through game-changing technologies, today announced the nominees for its future board of directors, effective upon the closing of Akili's business combination with Social Capital Suvretta H

      7/11/22 7:05:00 AM ET
      $DNAA
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DNAA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Jina Anil (Amendment)

      3/A - Akili, Inc. (0001850266) (Issuer)

      12/13/22 8:14:59 PM ET
      $DNAA
    • SEC Form 3 filed by new insider Ehlert Kenneth (Amendment)

      3/A - Akili, Inc. (0001850266) (Issuer)

      12/13/22 8:15:13 PM ET
      $DNAA
    • SEC Form 3 filed by new insider Martucci Walter Edward Ii (Amendment)

      3/A - Akili, Inc. (0001850266) (Issuer)

      12/13/22 8:10:52 PM ET
      $DNAA

    $DNAA
    Leadership Updates

    Live Leadership Updates

    See more
    • PureTech Founded Entity Akili Appoints Game Industry Veteran Behind Bejeweled, Plants vs. Zombies as Chief Product Officer

      Jon David brings deep expertise in building and launching engaging products to the Akili leadership team PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company noted that its Founded Entity, Akili Interactive Labs, Inc. ("Akili"), a leading digital medicine company developing cognitive treatments through game-changing technologies, today announced the appointment of Jon David as Chief Product Officer. In his role, David will be responsible for developing and executing the strategic vision of Akili's future product pipeline as the company continues to lead the way in establishing an entirely new category of medicine - one where

      3/17/22 9:05:00 AM ET
      $DNAA
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Game Industry Veteran Behind Bejeweled, Plants vs. Zombies Joins Akili as Chief Product Officer

      Jon David brings deep expertise in building and launching engaging products to the Akili leadership team Akili Interactive ("Akili" or the "Company"), a leading digital medicine company developing cognitive treatments through game-changing technologies, today announced the appointment of Jon David as Chief Product Officer. In his role, David will be responsible for developing and executing the strategic vision of Akili's future product pipeline as the company continues to lead the way in establishing an entirely new category of medicine - one where the treatment is experienced like high-end entertainment. Reporting to the CEO, David will join the Akili executive team, which includes leader

      3/17/22 9:00:00 AM ET
      $DNAA

    $DNAA
    SEC Filings

    See more
    • SEC Form 424B3 filed by Social Capital Suvretta Holdings Corp. I

      424B3 - Akili, Inc. (0001850266) (Filer)

      1/12/23 8:13:45 AM ET
      $DNAA
    • Social Capital Suvretta Holdings Corp. I filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Akili, Inc. (0001850266) (Filer)

      1/12/23 8:06:32 AM ET
      $DNAA
    • SEC Form 424B3 filed by Social Capital Suvretta Holdings Corp. I

      424B3 - Akili, Inc. (0001850266) (Filer)

      1/5/23 7:21:42 AM ET
      $DNAA

    $DNAA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Social Capital Suvretta Holdings Corp. I

      SC 13G - Akili, Inc. (0001850266) (Subject)

      1/20/23 6:27:44 AM ET
      $DNAA
    • SEC Form SC 13D filed by Social Capital Suvretta Holdings Corp. I

      SC 13D - Akili, Inc. (0001850266) (Subject)

      8/30/22 4:48:09 PM ET
      $DNAA
    • SEC Form SC 13G filed by Social Capital Suvretta Holdings Corp. I

      SC 13G - Akili, Inc. (0001850266) (Subject)

      8/29/22 12:28:20 PM ET
      $DNAA

    $DNAA
    Financials

    Live finance-specific insights

    See more
    • PureTech Founded Entity Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I

      In addition to PureTech's advanced Wholly Owned Pipeline, Founded Entities are an additional source of value and Akili is now set to join the growing list of publicly-traded Founded Entities for PureTech, which also include Karuna Therapeutics (NASDAQ:KRTX), Vor Biopharma (NASDAQ:VOR) and Gelesis (NYSE:GLS) Fully committed PIPE of $162 million led by $100 million from Social Capital with remaining $62 million from new and existing investors including: Suvretta Capital Management's Averill strategy, Apeiron Investment Group, Temasek, co-founder PureTech Health, Polaris Partners, Evidity Health Capital, JAZZ Venture Partners and Omidyar Technology Ventures Transaction values the combined co

      1/26/22 7:02:00 AM ET
      $DNAA
      $GLS
      $KRTX
      $PRTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I

      Akili's leading digital therapeutic platform combines science and technology to address cognitive impairments in patients, reimagining how central nervous system medicines are designed, developed, and delivered Transaction will support commercial launch of EndeavorRx®, a first-of-its-kind, FDA-cleared and CE-marked prescription digital therapeutic for pediatric ADHD, as well as advance clinical development pipeline across multiple neuropsychiatric diseases, including expanded ADHD populations, multiple sclerosis, autism, and depression Transaction values the combined company at an equity value post-money of up to approximately $1 billion and is expected to provide up to $412 million in

      1/26/22 7:00:00 AM ET
      $DNAA